Tenax Therapeutics Inc (TENX)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$1.72-2.27%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Tenax Therapeutics Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.38
Annual ending 2026-12-31
Revenue	—	4.16M
EPS	—	-1.454
Annual ending 2027-12-31
Revenue	—	12.9M
EPS	—	-1.447

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Cash funds operations through 2027	It expects cash to last through 2027.	Intact	Cash runs out before end of 2027	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Cash and cash equivalents increased from $97.6 million at 2025-Q4 to $118.0 million at 2026-Q2, aided by $13.4 million proceeds from warrant exercises. Management extended the cash runway to fund operations through mid-2028, exceeding the prior 2027 target, demonstrating delivery on capital allocation and liquidity management. Delivery assessment Oct 24, 2026
EPS loss narrows toward consensus estimates	A supporting condition in Tenax Therapeutics Inc's published investment case. The stated target is EPS loss improves to about -$1.39 in 2027.	Broken	EPS loss worsens beyond -$1.44 in 2026 or -$1.39 in 2027	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Share topline data from LEVEL study in Q3 2026	Tenax plans to share study data in Q3 2026.	Intact	Data not shared by Q3 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Management consistently expected topline data from the Phase 3 LEVEL trial in Q3 2026, confirmed by CEO statements in 2026-Q1 and 2026-Q2. The data release occurred as planned in August 2026, matching management's timeline and delivering on this key milestone. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-1.45

Unavailable → $-1.45 · observed estimates

FY2027 revenue$0.01B

$0.01B → $0.01B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	$12,900,000	4 / 6
2026-07-25	Unavailable	$12,900,000	4 / 6
2026-07-26	Unavailable	$12,900,000	4 / 6
2026-07-27	Unavailable	$12,900,000	4 / 6
2026-07-28	Unavailable	$12,900,000	4 / 6
2026-07-29	$-1.45	$0	6 / 9
2026-07-30	$-1.91	$12,900,000	5 / 9
2026-07-31	$-1.91	$12,900,000	5 / 9
2026-08-01	$-1.91	$12,900,000	5 / 9
2026-08-02	$-1.46	$0	6 / 9
2026-08-03	$-1.46	$0	6 / 9
2026-08-04	$-1.46	$0	6 / 9
2026-08-05	$-1.90	$12,900,000	5 / 9
2026-08-06	$-1.90	$12,900,000	5 / 9
2026-08-08	$-1.46	$0	6 / 9
2026-08-09	$-1.46	$0	6 / 9
2026-08-10	$-1.90	$12,900,000	5 / 9
2026-08-12	$-1.90	$12,900,000	5 / 9
2026-08-13	$-1.90	$12,900,000	5 / 9
2026-08-14	$-1.90	$12,900,000	5 / 9
2026-08-15	$-1.90	$12,900,000	5 / 9
2026-08-16	$-1.90	$12,900,000	5 / 9
2026-08-17	$-1.90	$12,900,000	5 / 9
2026-08-18	$-1.90	$12,900,000	5 / 9
2026-08-19	$-1.90	$12,900,000	5 / 9
2026-08-20	$-1.45	$12,900,000	6 / 9
2026-08-21	$-1.45	$12,900,000	6 / 9
2026-08-22	$-1.45	$12,900,000	6 / 9
2026-08-23	$-1.45	$12,900,000	6 / 9
2026-08-24	$-1.45	$12,900,000	6 / 9
2026-08-25	$-1.45	$12,900,000	6 / 9
2026-08-26	$-1.45	$12,900,000	6 / 9
2026-08-27	$-1.45	$12,900,000	6 / 9
2026-08-28	$-1.45	$12,900,000	6 / 9
2026-08-29	$-1.45	$12,900,000	6 / 9
2026-08-30	$-1.45	$12,900,000	6 / 9
2026-08-31	$-1.45	$12,900,000	6 / 9
2026-09-01	$-1.45	$12,900,000	6 / 9
2026-09-02	$-1.45	$12,900,000	6 / 9
2026-09-03	$-1.45	$12,900,000	6 / 9
2026-09-04	$-1.45	$12,900,000	6 / 9
2026-09-05	$-1.45	$12,900,000	6 / 9
2026-09-06	$-1.45	$12,900,000	6 / 9
2026-09-07	$-1.45	$12,900,000	6 / 9
2026-09-08	$-1.45	$12,900,000	6 / 9
2026-09-09	$-1.45	$12,900,000	6 / 9
2026-09-10	$-1.45	$12,900,000	6 / 9
2026-09-11	$-1.45	$12,900,000	6 / 9
2026-09-12	$-1.45	$12,900,000	6 / 9
2026-09-13	$-1.45	$12,900,000	6 / 9
2026-09-14	$-1.45	$12,900,000	6 / 9
2026-09-15	$-1.45	$12,900,000	6 / 9
2026-09-16	$-1.45	$12,900,000	6 / 9
2026-09-17	$-1.45	$12,900,000	6 / 9
2026-09-18	$-1.45	$12,900,000	6 / 9
2026-09-19	$-1.45	$12,900,000	6 / 9
2026-09-20	$-1.45	$12,900,000	6 / 9
2026-09-21	$-1.45	$12,900,000	6 / 9
2026-09-22	$-1.45	$12,900,000	6 / 9
2026-09-23	$-1.45	$12,900,000	6 / 9
2026-09-24	$-1.45	$12,900,000	6 / 9
2026-09-25	$-1.45	$12,900,000	6 / 9
2026-09-26	$-1.45	$12,900,000	6 / 9
2026-09-27	$-1.45	$12,900,000	6 / 9
2026-09-28	$-1.45	$12,900,000	6 / 9
2026-09-29	$-1.45	$12,900,000	6 / 9
2026-09-30	$-1.45	$12,900,000	6 / 9
2026-10-01	$-1.45	$12,900,000	6 / 9
2026-10-02	$-1.45	$12,900,000	6 / 9
2026-10-03	$-1.45	$12,900,000	6 / 9
2026-10-04	$-1.45	$12,900,000	6 / 9
2026-10-05	$-1.45	$12,900,000	6 / 9
2026-10-06	$-1.45	$12,900,000	6 / 9
2026-10-07	$-1.45	$12,900,000	6 / 9
2026-10-08	$-1.45	$12,900,000	6 / 9
2026-10-09	$-1.45	$12,900,000	6 / 9
2026-10-10	$-1.45	$12,900,000	6 / 9
2026-10-11	$-1.45	$12,900,000	6 / 9
2026-10-12	$-1.45	$12,900,000	6 / 9
2026-10-13	$-1.45	$12,900,000	6 / 9
2026-10-14	$-1.45	$12,900,000	6 / 9
2026-10-15	$-1.45	$12,900,000	6 / 9
2026-10-16	$-1.45	$12,900,000	6 / 9
2026-10-17	$-1.45	$12,900,000	6 / 9
2026-10-18	$-1.45	$12,900,000	6 / 9
2026-10-19	$-1.45	$12,900,000	6 / 9
2026-10-20	$-1.45	$12,900,000	6 / 9
2026-10-21	$-1.45	$12,900,000	6 / 9
2026-10-22	$-1.45	$12,900,000	6 / 9
2026-10-23	$-1.45	$12,900,000	6 / 9
2026-10-24	$-1.45	$12,900,000	6 / 9

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	7	0
2026-06-01	8	0
2026-07-01	10	0
2026-08-01	10	4
2026-09-01	7	4
2026-10-01	6	4

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 6 Buy / Strong Buy · 4 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Cash funds operations through 2027Direct metric needs a verified mapping
EPS loss narrows toward consensus estimatesPublished status: Broken
Share topline data from LEVEL study in Q3 2026Direct metric needs a verified mapping

Next proof point

Nov 11, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.8%Typical daily move · historical

Downside history

-92.6%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Tenax Therapeutics Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

TENX is a speculative clinical-stage healthcare investment, not an established earnings compounder. Its long-term thesis is on watch: recent signals improved, but recent financial performance remains below its industry cohort and the business is still loss-making.

What's priced into Tenax Therapeutics Inc

The valuation model has low confidence and shows a large premium versus peers, with optionality, or value tied to possible future outcomes, driving the gap. The evidence does not specify exactly what investors expect, and no valuation fragility gates have fired.

What the fundamentals likely do

Near term, TENX has delivered the planned Phase 3 LEVEL data release and extended its cash runway through mid-2028, while LEVEL-2 enrollment progress is mixed. Recent signals improved and a July earnings beat was recorded, but the company remains loss-making and the next report carries elevated miss risk.

What Tenax Therapeutics Inc hinges on

The multi-year thesis hinges on what the clinical data support and whether LEVEL-2 enrollment advances toward its expected completion by the end of 2027. Near term, a guidance cut or further labor-market weakening would add risk, while strong results and guidance from healthcare bellwethers could support sector sentiment.